One case of interstitial pneumonia caused by serplulimab injection

doi:10.19803/j.1672-8629.20230445

Abstract

Abstract: Objective To analyze the incidence of lung injury caused by serplulimab injection and related risk factors so as to provide data for clinical use. Methods The clinical data of one case of adverse reactions - interstitial pneumonia - caused by serplulimab injection was analyzed while the related literature was reviewed and summarized. Results One patient was treated with chemotherapy using injectable nedaplatin and etoposide injection in combination with serplulimab injection, who developed interstitial pneumonia during the 2nd course of combined chemotherapy (a total of three courses), which was determined to be due to the serplulimab injection by correlation analysis. The incidence of lung injury caused by serplulimab injection ranged from 1.6% to 8.2% according to literature, and the associated risk factors included history of smoking, history of tobacco exposure, poor health status, age, underlying lung disease and history of lung radiotherapy. This injection was recommended for use in patients under 65. Conclusion Clinicians are to be alert to the risk of interstitial pneumonia attributed to serplulimab injection. Prior to medication, thorough assessment of potential risk factors is crucial, and precautions need to be taken. During medication, respiratory symptoms of the patient should be closely monitored. In case of drug-related lung injury, pulmonary imaging, pulmonary function and arterial blood gas of the patient have to be examined before the severity is assessed to ensure quick interventions and safety of the patient.

Key words: serplulimab, injection, drug-related lung injury, interstitial pneumonia, adverse drug reaction

CLC Number:

R979.1

CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230445

https://www.zgywjj.com/EN/Y2024/V21/I2/213

References

[1] LEE A.Serplulimab: first approval[J]. Drugs, 2022, 82(10): 1137-1141.
[2] QIN S, LI J, ZHONG H, et al.Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: a single-arm, multicenter, phase 2 study[J]. J Clin Oncol, 2021, 39(15): 2566-2566.
[3] SONG Y, ZHANG B, XIN D, et al.First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial[J]. Nat Med, 2023, 29(2): 473-482.
[4] CHENG Y, HAN L, WU L, et al.Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial[J]. JAMA, 2022, 328(12): 1223-1232.
[5] SHANGHAI HENLIUS BIOTECH, INC. Serplulimab injection: Chinese prescribing information[EB/OL].[2023-11-02].https://www.henlius.com/marketed-products.html.
[6] QIN S, LI J, ZHONG H, et al.Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial[J]. Br J Cancer, 2022,127(12): 2241-2248.
[7] OMOTANI S, ISHIZAKA T, INOUE M, et al.Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir[J]. J Pharm Health Care Sci, 2020, 6: 6.
[8] FAN JJ, ZHAO L.Research status on the drug-induced lung injury[J]. The Chinese Journal Clinical Pharmacology(中国临床药理学杂志), 2022, 38(10): 1123-1127.
[9] KUDOH S, KATO H, NISHIWAKI Y, et al.Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study[J]. Am J Respir Crit Care Med, 2008, 177: 1348-1357.
[10] Lung Cancer Group, Respiratory Branch, Chinese Medical Association.Expert consensus on the diagnosis and treatment of immune checkpoint inhibitor associated pneumonia[J]. Chin J Tuberc Respir Dis(中华结核和呼吸杂志), 2019, 42(11): 820-825.
[11] ZAZZARA MB, PALMER K, VETRANO DL, et al.Adverse drug reactions in older adults: a narrative review of the literature[J]. Eur Geriatr Med, 2021, 12(3): 463-473.
[12] WANG S, LI Y, LIU Z, et al.Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a network meta-analysis[J]. Lung Cancer, 2023, 178: 47-56.
[13] SHIRASAWA M, NAKAHARA Y, NIWA H, et al.Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer[J]. Mol Clin Oncol, 2016, 5(6): 714-716.
[14] National Center for Adverse Drug Reaction Monitoring. Guidelines for the Use of Terminology in Adverse Drug Reactions[S]. National Center for Adverse Drug Reaction Monitoring, 2016.
[15] LIU LH, AHI B, YE LP, et al.Acute extensive pulmonary toxicity from chemotherapeutic agents-two cases report and review of literatures[J]. Journal of Clinical Pulmonary Medicine(临床肺科杂志), 2012, 17(3): 392-394.